When was Constellation Pharma founded?

Constellation Pharma was founded in 2008 and raised its 1st funding round within a year of its incorporation.

Where is Constellation Pharma located?

Constellation Pharma is headquartered in Cambridge, United States.

How many employees does Constellation Pharma have?

As of Dec 31, 2021, Constellation Pharma has 142 employees, reflecting a 4% year-over-year decline in headcount.

Is Constellation Pharma a funded company?

Constellation Pharma is a funded company, having raised a total of $349M across 9 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Apr 29, 2008.

When was the latest funding round of Constellation Pharma?

Constellation Pharma's latest funding was a $***** Post IPO round on Oct 01, 2019, with participation from 3 investors. Its primary sector is Genomics. In United States, the Genomics sector has seen $1.84B in funding in 2026 to date.

Where does Constellation Pharma rank among its competitors?

Constellation Pharma ranks 155th amongst 539 active competitors, of which 198 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Sirnaomics, which secured $17.7M in Sep, 2025.

Who are the top competitors of Constellation Pharma?

Constellation Pharma's top competitors include Alnylam, Spark Therapeutics and Forge Biologics. Among them, Sirnaomics secured the most recent funding round in September, 2025.

Constellation Pharma - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of drugs in the field of epigenetics. The pipeline includes bromodomain and extra-terminal proteins that regulate gene expression and small molecule inhibition and EZH2, a histone lysine methyltransferase that works cooperatively as part of a multi-subunit complex known as PRC2.

Website: constellationpharma.com
Social

Key Metrics

Founded Year

2008

Location

Cambridge, United States

Stage

Acquired

Total Funding

$349M in 9 rounds

Latest Funding Round

Post IPO, Oct 01, 2019, $*****

Investors

Venrock & 19 more

Ranked

155^th among 539 active competitors

Employee Count

142 as on Dec 31, 2021

Similar Companies

Alnylam & 673 more

Exit Details

Acquired by MorphoSys (Jun 02, 2021)

View Constellation Pharma's full profile

Constellation Pharma got acquired by MorphoSys on Jun 02, 2021 at an acquisition amount of $*****.

Click here to take a look at Constellation Pharma's acquisition in detail

Constellation Pharma has raised a total funding of $349M over 9 rounds. Its first funding round was on Apr 29, 2008. Its latest funding round was a Post IPO round on Oct 01, 2019 for $*****. 3 investors participated in its latest round. Constellation Pharma has 20 institutional investors.

Here is the list of recent funding rounds of Constellation Pharma:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 01, 2019	6821685	Post IPO	5546765	7592489	4119271	8650067
Apr 09, 2018	9316648	Series E	4361510	4094501	6495433	The Column Group & 5 more
Sep 23, 2016	6404803	Series D	7481645	2257611	3358235	5378828

Access funding benchmarks and valuations. Sign up today!

View details of Constellation Pharma's funding rounds and investors

The founders of Constellation Pharma are Yang Shi, David Allis and Danny Reinberg.

Here are the details of Constellation Pharma's key team members:

Yang Shi: Co-Founder of Constellation Pharma.
David Allis: Co-Founder of Constellation Pharma.
Danny Reinberg: Co-Founder of Constellation Pharma.

View details of Constellation Pharma's Founder profiles and Board Members

Constellation Pharma's employee count trend

Constellation Pharma has 142 employees as of Dec 21. The total employee count is 4.0% lower than what it was in Dec 20. Here is Constellation Pharma's employee count trend over the years:

Employee count trend for Constellation Pharma

Uncover Constellation Pharma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Constellation Pharma include Alnylam, Spark Therapeutics and Forge Biologics. Here is the list of Top 10 competitors of Constellation Pharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	79/100
2nd	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, T. Rowe Price & 6 others	73/100
3rd	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	Aisling Capital, Xontogeny & 7 others	70/100
4th	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Foresite Capital & 18 others	70/100
5th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	69/100
6th	Ultragenyx 2010, Novato (United States), Acquired	Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases	$135M	F-Prime Capital, Adage Capital Management ... & 10 others	69/100
7th	Passage Bio 2017, Philadelphia (United States), Public	Developer of gene therapies for CNS rare diseases	$226M	Access Biotechnology, Orbimed & 10 others	69/100
8th	ElevateBio 2018, Cambridge (United States), Series D	Provider of transnational research for portfolio of cell and gene therapy	$1.25B	Matrix Capital Management, Citadel & 16 others	69/100
9th	Sirnaomics 2007, Gaithersburg (United States), Public	Developer of RNA based therapeutics for the treatment of cancer and fibrosis disease	$267M	Rotating Boulder Fund, Walvax & 16 others	67/100
10th	Krystal Biotech 2015, Pittsburgh (United States), Public	Developer of genetic medicines to treat rare diseases	$11.3M	Frazier Life Sciences, Danforth Advisors & 2 others	67/100
155th	Constellation Pharma 2008, Cambridge (United States), Acquired	Developer of drugs in the field of epigenetics	$349M	Bain Capital Life Sciences, Venrock & 18 others	45/100